P1060: REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE

Benzer Materyaller

• P1060: REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE
  Yazar:: J. Mascarenhas, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-06-01)
• Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
  Yazar:: Bewersdorf JP, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-12-01)
• P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
  Yazar:: V. Gupta, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-06-01)
• P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
  Yazar:: F. Passamonti, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-06-01)
• P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
  Yazar:: P. Abraham, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-06-01)